LifeAgain Announces Support Of The American Cancer Society's Recommendations For Early Prostate Cancer Screening

LifeAgain BlueMetric Select Term Life Insurance - First Program Designed for Men with Active Localized Prostate Cancer

News provided by

Oct 08, 2013, 12:00 ET

SAN DIEGO, Oct. 8, 2013 /PRNewswire/ -- LifeAgain Insurance Solutions, Inc., a wholly-owned subsidiary of Cardium Therapeutics, today announced support of the American Cancer Society's recommendation that men have the opportunity to make informed decisions about early screening for prostate cancer. Two initial tests commonly used to screen for prostate cancer when there are no symptoms include a prostate-specific antigen (PSA) blood test and a digital rectal exam (DRE).

(Info: http://photos.prnewswire.com/prnh/20131008/LA93564-INFO)

(Logo: http://photos.prnewswire.com/prnh/20130919/LA82808LOGO)

The American Cancer Society recommends that physicians discuss the pros and cons of testing with their patients starting at age 50 if there is an average risk of prostate cancer and life expectancy is at least 10 years. Discussions should take place starting at age 45 for men at high risk, including African-American men and men who have had a first-degree relative diagnosed with prostate cancer at a young age (under 65 years of age). Men with more than one first-degree relative who had prostate cancer at an early age should start discussions with their physicians about prostate cancer screening at age 40.

If no prostate cancer is found at initial screening, future screening is dependent on the results of the PSA blood test. Men should be tested yearly if the PSA level is 2.5 ng/ml or higher and every two years if the PSA level is less than 2.5 ng/ml. Physicians should also take into account the overall health of their patients, and not just age, when making decisions about early screening and retesting. Patients are encouraged to discuss these and other recommendations of the American Cancer Society with their physicians.

Prostate cancer is the most common non-skin cancer in America, affecting 1 in 6 men. In 2013, more than 238,000 men will be diagnosed with prostate cancer, and more than 30,000 men will die from the disease. It is estimated that over the next 10 years in the United States, approximately 8 million men under age 64 will be determined to have elevated PSA scores without formal determination of prostate cancer, and 1 million men under age 64 will be diagnosed with prostate cancer. Overall, 1.6 million men have elevated PSA, and about 30 percent of them will be diagnosed with prostate cancer.

Many men discover they have prostate cancer as a result of a PSA blood test during their medical exams when applying for life insurance. Currently, men with elevated PSA scores and active localized prostate cancer usually are considered uninsurable based on traditional life insurance underwriting standards. Pioneering this field, LifeAgain recently introduced the first term life insurance for men with active localized prostate cancer. LifeAgain's BlueMetric Select™ program was specifically designed to enable life insurance companies to provide eligible men with term life insurance coverage following a prostate cancer diagnosis or upon the completion of a prostate cancer surgery, without the traditional multi-year waiting periods and additional medical re-qualifications generally required by most life insurance companies. Importantly, it is available to prostate cancer patients who are in a "watchful waiting" treatment plan, including younger men who traditionally have been denied life insurance with few exceptions. The BlueMetric Select program was developed based on LifeAgain's Advanced Medical Data Analytics Platform Technology (ADAPT™). Additional information about the BlueMetric Select Program is available at www.lifeagain.com.

About LifeAgain
LifeAgain Insurance Solutions, Inc. is an advanced medical data analytics business and life insurance agency that is focused on the development, marketing and sale of "survivable risk" term life insurance programs for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional underwriting standards. Working in cooperation with large and established life insurance companies, LifeAgain uses new actuarial methods, and scientific and medical data-driven insights to design life insurance solutions for those who may otherwise not be able to obtain coverage. LifeAgain's initial focus is on the development, marketing and sale of survivable risk life insurance for men with active localized prostate cancer. LifeAgain plans to develop additional new and innovative life insurance solutions for men and women with other medical conditions. Additional information is available at www.lifeagain.com.

Forward-Looking Statements
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are necessarily based on estimates and assumptions that are inherently subject to significant business, economic, and competitive uncertainties and contingencies, many of which are beyond our control and subject to change. Moreover, we operate in a rapidly changing and competitive environment. These uncertainties and contingencies could cause actual results to differ materially from those expressed, and therefore undue reliance should not be placed upon such statements. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this report.

LifeAgain Insurance Solutions, Inc. is a life insurance agency incorporated in Delaware and registered in New York as LifeAgain Insurance Services. Insurance issued under the BlueMetric Select program may not be available in all states.

For the education of Life Insurance Producers and Brokers Only – not for public use.

LifeAgain^®, BlueMetric Select™, Decision Rule Adaption™, and ADAPT™ are trademarks of
LifeAgain Insurance Solutions, Inc. or Cardium Therapeutics, Inc.
Other trademarks belong to their respective owners.

SOURCE LifeAgain